https://www.selleckchem.com/pr....oducts/jh-x-119-01.h
No neurological deterioration was observed. Ten of 106 (9.4%) patients were under anticoagulation therapy, and 28 of 106 (26.4%) were under antiplatelet therapy. ISAH in mTBI seems to be a radiological stable entity over 72h with no neurological deterioration. The clinical utility of a repeat head CT in such patients is questionable, considering its radiation exposure and cost. Regardless of anticoagulation/antiplatelet therapy, neurologic observation and symptomatic treatment solely could be a reasonable alternative. ISAH in mTBI s
Like
Comment
Share
